On July 3, Bloomberg News reported that AstraZeneca (NASDAQ: AZN) is in discussions with Summit Therapeutics for a licensing agreement concerning an experimental lung cancer drug, with a potential ...

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ivonescimab.

Datroway is the first and only TROP2-directed antibody-drug conjugate (ADC) approved in the U.S. for lung cancer. The drug is jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

Copycats, unrealistic expectations, and budget cuts are AI’s gifts to graphic artists.

The aim is to find and treat lung cancers early, before they grow and spread, to improve the chance of survival. Here’s what’s involved.

After a scary incident in the Phoenix Mercury's game against the New York Liberty, here's the latest news on Lexi Held's collapsed lung.

AstraZeneca has started the process to improve its cancer treatment capabilities with an addition to its campus in southwest Frederick.

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in ...

FDA expands AstraZeneca's Datroway label, making it the first TROP2-directed lung cancer therapy approved in the United States.

By Adam Whittaker AstraZeneca and Daiichi Sankyo's Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer.

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due.

Photo: rachel wisniewski/Reuters AstraZeneca and Daiichi Sankyo’s Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer.